Influenza affects 15-60 million people in the United States each year, causing an estimated 44,000 deaths and 186,000 hospitalizations annually. Pandemic influenza has occurred three times over the last century. The 1918 outbreak alone killed more than 40 million people worldwide. Avian influenza (bird flu) is a lethal influenza strain that has created worldwide concern because its infection can be transferred among humans. The mortality rate among humans exceeds 50%.

immuron is developing Flubody, a revolutionary solution that contains colostrum - derived anti-flu virus antibodies for oral delivery.  The all-natural product  will provide immediate-acting immune enhancement once deposited topically on mucosal surfaces that come in contact with the influenza virus. Flubody will be addressing both seasonal and avian influenza (bird flu) virus strains.

The company conducted several successful animal trials with mice, led by an internationally-recognized influenza research group at the University of Melbourne led by Professor Lorena Brown, using recognized pathways for development of anti-avian flu virus treatments.

The dairy derived anti-flu virus antibody significantly decreased disease mortality and were significantly interrupting the disease process after challenges with lethal doses of virus. Anadis prototype milk-derived hyperimmune antibody preparation ("flubody") improved the survival rate of infected mice (exposed to lethal flu) from 0% in non-treated mice to up to 60% in treated mice. In other trials, it was shown that the progress of disease could be delayed for days with a single application of the prototype formulatio